Way cleared for Hoechst merger
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AFTER A last-minute revision the German drugs group Hoechst agreed last night to buy Rhone-Poulenc of France in a share swap, a source close to the French company said. The new company, Aventis SA, will become the world's largest producer of drugs.
The agreement allows Hoechst shareholders to gain 53 per cent of Aventis. It was revised to win the backing of Kuwait Petroleum Corp (KPC), which owns 24.5 per cent of Hoechst. Hoechst said KPC management approved the plan, though its board has yet to clear it. The earlier plan envisaged a 50:50 venture. Hoechst will spin off its bulk chemicals unit Celanese and plastics division Ticona in October. The companies will swap shares in November and create the new Strasbourg-based company.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments